StanfordLee-YuPengMDPhD

Rheumatology • Seattle, WA

Lupus & Related, Rheumatoid Arthritis & Related, Scleroderma & Related, Spondyloarthropathy

Physician

Join to view full profile

Dr. Peng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Peng's full profile

Already have an account?

Office
188 E Blaine St
Ste 200
Seattle, WA 98102
Phone+1 206-785-4545

Fax+1 206-316-8383

Education & Training

Brigham and Women's HospitalFellowship, Rheumatology, 2002
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999
University of Pennsylvania Health SystemInternship, Internal Medicine, 1997 - 1998
Yale School of MedicineClass of 1997

Certifications & Licensure

WA State Medical License 2008 - 2026
CA State Medical License 2005 - 2025
PA State Medical License 1998 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
Fellow (FACP) American College of Physicians, 2012
Fellow American College of Rheumatology

Clinical Trials

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Start of enrollment: 2008 Jan 01
Completed
Phase 2, Phase 3
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Start of enrollment: 2008 Jul 01
Completed
Phase 2
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Start of enrollment: 2009 May 01
Completed
Phase 2
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines Start of enrollment: 2009 Sep 01
Completed
Phase 4
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX Start of enrollment: 2010 Jan 01
Completed
Phase 3
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA) Start of enrollment: 2010 Sep 01
Completed
Phase 4
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) Start of enrollment: 2010 Oct 01
Completed
Phase 3
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Start of enrollment: 2010 Dec 01
Completed
Phase 3
Study on the Safety of Abatacept in Relapsing Polychondritis Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Start of enrollment: 2011 Mar 31
Completed
Phase 2
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Start of enrollment: 2016 Sep 23
Terminated
Phase 1, Phase 2
Cell Surface Marker Expression in Autoimmune Diseases Start of enrollment: 2019 Jun 12
Completed
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies Start of enrollment: 2020 Jun 02
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

308 citations
NFATc1 and NFATc2 Together Control Both T and B Cell Activation and Differentiation
Stanford L. Peng, Andrea J. Gerth, Ann M. Ranger, Laurie H. Glimcher
Immunity. 2001-01-01
354 citations
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern
The Lancet. Oncology. 2017-01-01
571 citations
Oocyte-Specific Deletion of Pten Causes Premature Activation of the Primordial Follicle Pool
Pradeep Reddy, Lian Liu, Deepak Adhikari, Krishna Jagarlamudi, Singareddy Rajareddy
Science. 2008-02-01

Abstracts/Posters

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (...
Stanford L. Peng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

“Switch” Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Pot...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

Overview of cryoglobulins and cryoglobulinemia
Peng SL, Schur PH
http://www.uptodate.com/contents/overview-of-cryoglobulins-and-cryoglobulinemia
UpToDate, Wolters Kluwer Health - 2013-04-10
Cryofibrinogenemia
Peng SL
http://www.uptodate.com/contents/cryofibrinogenemia
UpToDate, Wolters Kluwer Health - 2012-07-06

Press Mentions

Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (Pembrolizumab)June 30th, 2021
ASCO: Alpine Reports 61% 'Clinical Benefit' in Early Trial of CD28-Targeted Immuno-Oncology DrugJune 7th, 2021

Grant Support

Molecular Mechanisms Of Autoreactive B Cell ActivationNational Institute Of Allergy And Infectious Diseases2005–2007
Molecular Mechanisms Of Autoreactive B Cell ActivationNational Institute Of Allergy And Infectious Diseases2004–2005
Forkhead Transcription Factors In T LymphocytesNational Institute Of Allergy And Infectious Diseases2004
The Function Of T-BET In T Helper Cell DevelopmentNational Institute Of Allergy And Infectious Diseases2002–2003
The Function Of T-BET In T Helper Cell DevelopmentNational Institute Of Allergy And Infectious Diseases2000–2001

External Links

Virginia Mason Medical Centerhttp://www.virginiamason.org
Benaroya Research Institutehttp://www.benaroyaresearch.org